Literature DB >> 18042477

Identification and pretherapy susceptibility of pathogens in patients with complicated urinary tract infection or acute pyelonephritis enrolled in a clinical study in the United States from November 2004 through April 2006.

Janet Peterson1, Simrati Kaul, Mohammed Khashab, Alan Fisher, James B Kahn.   

Abstract

OBJECTIVE: The purpose of this study was to assess the pretherapy microbiology and fluoroquinolone susceptibility of pathogens from 650 patients with complicated urinary tract infection (cUTI) or acute pyelonephritis (AP) as part of a multicenter, randomized, controlled clinical trial.
METHODS: In this post hoc analysis of a multicenter, randomized, double-blind study, adults with a clinical diagnosis of cUTI or AP were recruited from 130 community-based and institution-based study centers in the United States from November 2004 through April 2006. Urine and blood culture specimens were identified and tested for susceptibility according to Clinical and Laboratory Standards Institute methods. Presence of a pathogen in the urine culture was confirmed by a colony count of =105 colony-forming units per milliliter. Susceptibility to nonstudy drugs (trimethoprim/sulfamethoxazole [TMP/SMX] and ampicillin) and to study drugs (levofloxacin and ciprofloxacin) was categorized as susceptible, intermediate, or resistant.
RESULTS: Six hundred fifty patients (417 women, 233 men; age range, 18-94 years) with a diagnosis of cUTI or AP were recruited. A total of 68.2% patients (224 men, 219 women) were diagnosed with cUTI, and 31.8% (198 women, 9 men), with AP. Most (646/650 [99.4%]) infections were community acquired. The most common pathogen was Escherichia coli (65.6%), although 12.2% of patients had gram-positive pathogens. Testing for susceptibility to ampicillin and TMP/SMX found that 50.1% and 22.1% of gramnegative pathogens were fully resistant to ampicillin and TMP/SMX, respectively. However, 91.9% of isolates were susceptible to levofloxacin and ciprofloxacin, with 6.5% of isolates resistant or intermediately resistant to levofloxacin, and 9.7% of isolates resistant or intermediately resistant to ciprofloxacin at study entry (P < 0.001 [Stuart-Maxwell test]). All isolates resistant to levofloxacin were also resistant to ciprofloxacin, whereas 6 isolates that were fully susceptible to levofloxacin were fully resistant to ciprofloxacin.
CONCLUSION: In this study, the level of fluoroquinolone susceptibility of urinary pathogens was high (90.6% in cUTI; 98.1% in AP).

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18042477     DOI: 10.1016/j.clinthera.2007.10.008

Source DB:  PubMed          Journal:  Clin Ther        ISSN: 0149-2918            Impact factor:   3.393


  4 in total

1.  Microbial Etiology and Antimicrobial Susceptibility of Bactria Implicated in Urinary Tract Infection in Tehran, Iran.

Authors:  Zohreh Nozarian; Alireza Abdollahi
Journal:  Iran J Pathol       Date:  2015

2.  Incidence, microbiological profile of nosocomial infections, and their antibiotic resistance patterns in a high volume Cardiac Surgical Intensive Care Unit.

Authors:  Manoj Kumar Sahu; Bharat Siddharth; Arin Choudhury; Sreenivas Vishnubhatla; Sarvesh Pal Singh; Ramesh Menon; Poonam Malhotra Kapoor; Sachin Talwar; Shiv Choudhary; Balram Airan
Journal:  Ann Card Anaesth       Date:  2016 Apr-Jun

3.  Outcomes of high-dose levofloxacin therapy remain bound to the levofloxacin minimum inhibitory concentration in complicated urinary tract infections.

Authors:  Eliana S Armstrong; Janelle A Mikulca; Daniel J Cloutier; Caleb A Bliss; Judith N Steenbergen
Journal:  BMC Infect Dis       Date:  2016-11-25       Impact factor: 3.090

4.  Retrospective analysis of nosocomial infections in the intensive care unit of a tertiary hospital in China during 2003 and 2007.

Authors:  Ji-Guang Ding; Qing-Feng Sun; Ke-Cheng Li; Ming-Hua Zheng; Xiao-Hui Miao; Wu Ni; Liang Hong; Jin-Xian Yang; Zhan-Wei Ruan; Rui-Wei Zhou; Hai-Jiao Zhou; Wen-Fei He
Journal:  BMC Infect Dis       Date:  2009-07-25       Impact factor: 3.090

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.